Barr's Generic Biologics Strategy Includes Outsourcing Manufacturing
This article was originally published in The Pink Sheet Daily
Executive Summary
The value of generic biologics will not come from manufacturing but rather from "navigating the regulatory and legal arena," CEO Downey says. Barr plans to detail its business plan by next June.
You may also be interested in...
Generic Biologics Provide Significant Growth Opportunity, Barr Says
Barr plans to limit its biotech projects to four until a regulatory pathway for follow-on biologics is established, CEO Downey says. The generic industry is arguing for “common sense” rules, he asserts.
Generic Biologics Provide Significant Growth Opportunity, Barr Says
Barr plans to limit its biotech projects to four until a regulatory pathway for follow-on biologics is established, CEO Downey says. The generic industry is arguing for “common sense” rules, he asserts.
FDA Follow-On Biologics Guidance Will Follow Public Workshop, Agency Tells Senate Committee
A public scientific workshop is planned for late summer; timing or content of a guidance cannot be predicted until after the meeting, Acting Commissioner Crawford tells Senate Judiciary Committee. Sen. Schumer expresses concern that progress towards "generic" biologics is "slowing."